Please enter exact key words
A Novel Prokineticin Receptor 1 (PKR1) Signaling Inhibitor

for the Treatment of Inflammatory Diseases

Home / Available Projects / A Novel Prokineticin Receptor 1 (PKR1) Signaling Inhibitor
Drug Name GPCR-targeted Project 005

Prokineticins (PK1 and PK2) are peptide hormones that exert their biological activities, such as modulating cell survival, cell motility, and cell excitability, through two common G-protein-coupled receptors: prokineticin receptor (PKR) 1 and 2. A monoclonal antibody is being developing as an inhibitor of prokineticin receptor 1 (PKR1) for the treatment of inflammation. Early research is under way.

Target Prokineticin receptor 1 (PKR1)
Drug Modality Monoclonal antibody
Indication Inflammation
Product Category Biologic
Mechanism of Action PKR1 inhibitors
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.